<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11551">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00564447</url>
  </required_header>
  <id_info>
    <org_study_id>041-102</org_study_id>
    <secondary_id>P08654</secondary_id>
    <nct_id>NCT00564447</nct_id>
  </id_info>
  <brief_title>Study of AzaSite (Azithromycin) Versus Vigamox in the Conjunctiva of Healthy Volunteers</brief_title>
  <official_title>A Single-Center, Open-Label, Randomized Study of the Pharmacokinetics of AzaSite Ophthalmic Solution Versus Vigamox in the Conjunctiva of Healthy Volunteers Following a Single Ocular Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the drug concentrations of AzaSiteâ„¢ compared to
      Vigamox at various time points in conjunctiva tissue of healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Assessment of Pharmacokinetic Parameters</measure>
    <time_frame>Up to 24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Pharmacokinetic Parameters</measure>
    <time_frame>Over 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Conjunctiva Concentration of Azithromycin and Moxifloxacin</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Bacterial Infections</condition>
  <condition>Eye Infections</condition>
  <arm_group>
    <arm_group_label>Azithromycin-30 minutes Post dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin-2 hours post dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin-12 hours post dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin-24 hours post dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin-30 minutes post dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin-2 hours post dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin-12 hours post dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxafloxacin-24 hours post dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>azithromycin topical solution 1% given as a single drop in a single eye</description>
    <arm_group_label>Azithromycin-30 minutes Post dose</arm_group_label>
    <arm_group_label>Azithromycin-2 hours post dose</arm_group_label>
    <arm_group_label>Azithromycin-12 hours post dose</arm_group_label>
    <arm_group_label>Azithromycin-24 hours post dose</arm_group_label>
    <other_name>AzaSite</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Moxifloxacin topical solution given as a single drop in a single eye</description>
    <arm_group_label>Moxifloxacin-30 minutes post dose</arm_group_label>
    <arm_group_label>Moxifloxacin-2 hours post dose</arm_group_label>
    <arm_group_label>Moxifloxacin-12 hours post dose</arm_group_label>
    <arm_group_label>Moxafloxacin-24 hours post dose</arm_group_label>
    <other_name>Vigamox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have best corrected visual acuity of 0.60 logMAR or better in each eye as measured
             using Early Treatment of Diabetic Retinopathy Study chart

        Exclusion Criteria:

          -  Have a known allergy and/or sensitivity to the test article(s) or its components or
             any therapies associated with the trial

          -  Have active signs or symptoms of any clinically significant ocular disorder (other
             than refractive disorders)

          -  Have a known bleeding disorder or history of bleeding complications after surgical or
             dental procedures

          -  Take aspirin, or take any other blood thinners or anti-coagulants (e.g. warfarin)
             including prescription, over the counter, or homeopathic therapies

          -  Have undergone any ocular surgical intervention within 3 months prior to Visit 1 or
             anticipate having ocular surgery during the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reza Haque</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2011</verification_date>
  <lastchanged_date>September 20, 2011</lastchanged_date>
  <firstreceived_date>November 20, 2007</firstreceived_date>
  <firstreceived_results_date>June 27, 2011</firstreceived_results_date>
  <responsible_party>
    <name_title>Saiid Davari</name_title>
    <organization>Inspire Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Eye Infections</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>December 2007</recruitment_details>
      <pre_assignment_details>Normal volunteers</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Azithromycin Ophthalmic Solution, 1% -30 Minutes Post Dose</title>
        </group>
        <group group_id="P2">
          <title>Azithromycin Ophthalmic Solution, 1% -2 Hours Post Dose</title>
        </group>
        <group group_id="P3">
          <title>Azithromycin Ophthalmic Solution, 1% -12 Hours Post Dose</title>
        </group>
        <group group_id="P4">
          <title>Azithromycin Ophthalmic Solution, 1% -24 Hours Post Dose</title>
        </group>
        <group group_id="P5">
          <title>Moxifloxacin 0.5% Ophthalmic Solution-30 Minutes Post Dose</title>
        </group>
        <group group_id="P6">
          <title>Moxifloxacin 0.5% Ophthalmic Solution-2 Hours Post Dose</title>
        </group>
        <group group_id="P7">
          <title>Moxifloxacin 0.5% Ophthalmic Solution-12 Hours Post Dose</title>
        </group>
        <group group_id="P8">
          <title>Moxifloxacin 0.5% Ophthalmic Solution-24 Hours Post Dose</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Azithromycin Ophthalmic Solution, 1% -30 Minutes Post Dose</title>
        </group>
        <group group_id="B2">
          <title>Azithromycin Ophthalmic Solution, 1% -2 Hours Post Dose</title>
        </group>
        <group group_id="B3">
          <title>Azithromycin Ophthalmic Solution, 1% -12 Hours Post Dose</title>
        </group>
        <group group_id="B4">
          <title>Azithromycin Ophthalmic Solution, 1% -24 Hours Post Dose</title>
        </group>
        <group group_id="B5">
          <title>Moxifloxacin 0.5% Ophthalmic Solution-30 Minutes Post Dose</title>
        </group>
        <group group_id="B6">
          <title>Moxifloxacin 0.5% Ophthalmic Solution-2 Hours Post Dose</title>
        </group>
        <group group_id="B7">
          <title>Moxifloxacin 0.5% Ophthalmic Solution-12 Hours Post Dose</title>
        </group>
        <group group_id="B8">
          <title>Moxifloxacin 0.5% Ophthalmic Solution-24 Hours Post Dose</title>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="6"/>
                <measurement group_id="B4" value="6"/>
                <measurement group_id="B5" value="6"/>
                <measurement group_id="B6" value="6"/>
                <measurement group_id="B7" value="6"/>
                <measurement group_id="B8" value="6"/>
                <measurement group_id="B9" value="48"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="44.5" spread="11.1"/>
                <measurement group_id="B2" value="46.8" spread="13.1"/>
                <measurement group_id="B3" value="38.2" spread="13.2"/>
                <measurement group_id="B4" value="33.7" spread="16.8"/>
                <measurement group_id="B5" value="43.0" spread="13.7"/>
                <measurement group_id="B6" value="43.5" spread="13.2"/>
                <measurement group_id="B7" value="33.3" spread="8.2"/>
                <measurement group_id="B8" value="36.7" spread="11.7"/>
                <measurement group_id="B9" value="40.0" spread="12.8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="2"/>
                <measurement group_id="B4" value="3"/>
                <measurement group_id="B5" value="1"/>
                <measurement group_id="B6" value="5"/>
                <measurement group_id="B7" value="2"/>
                <measurement group_id="B8" value="3"/>
                <measurement group_id="B9" value="23"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="4"/>
                <measurement group_id="B4" value="3"/>
                <measurement group_id="B5" value="5"/>
                <measurement group_id="B6" value="1"/>
                <measurement group_id="B7" value="4"/>
                <measurement group_id="B8" value="3"/>
                <measurement group_id="B9" value="25"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="6"/>
                <measurement group_id="B4" value="6"/>
                <measurement group_id="B5" value="6"/>
                <measurement group_id="B6" value="6"/>
                <measurement group_id="B7" value="6"/>
                <measurement group_id="B8" value="6"/>
                <measurement group_id="B9" value="48"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Pharmacokinetic Parameters</title>
        <time_frame>Up to 24 hours</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Pharmacokinetic Parameters</title>
        <description>Conjunctiva Concentration of Azithromycin and Moxifloxacin</description>
        <time_frame>Over 24 hours</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin Ophthalmic Solution, 1% -30 Minutes Post Dose</title>
          </group>
          <group group_id="O2">
            <title>Azithromycin Ophthalmic Solution, 1% -2 Hours Post Dose</title>
          </group>
          <group group_id="O3">
            <title>Azithromycin Ophthalmic Solution, 1% -12 Hours Post Dose</title>
          </group>
          <group group_id="O4">
            <title>Azithromycin Ophthalmic Solution, 1% -24 Hours Post Dose</title>
          </group>
          <group group_id="O5">
            <title>Moxifloxacin 0.5% Ophthalmic Solution-30 Minutes Post Dose</title>
          </group>
          <group group_id="O6">
            <title>Moxifloxacin 0.5% Ophthalmic Solution-2 Hours Post Dose</title>
          </group>
          <group group_id="O7">
            <title>Moxifloxacin 0.5% Ophthalmic Solution-12 Hours Post Dose</title>
          </group>
          <group group_id="O8">
            <title>Moxifloxacin 0.5% Ophthalmic Solution-24 Hours Post Dose</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="6"/>
                  <measurement group_id="O5" value="6"/>
                  <measurement group_id="O6" value="6"/>
                  <measurement group_id="O7" value="6"/>
                  <measurement group_id="O8" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Assessment of Pharmacokinetic Parameters</title>
            <description>Conjunctiva Concentration of Azithromycin and Moxifloxacin</description>
            <units>Î¼g/g</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="130.8" spread="89.1"/>
                  <measurement group_id="O2" value="51.6" spread="26.0"/>
                  <measurement group_id="O3" value="67.1" spread="51.8"/>
                  <measurement group_id="O4" value="31.9" spread="20.4"/>
                  <measurement group_id="O5" value="1.9" spread="2.0"/>
                  <measurement group_id="O6" value="3.8" spread="9.0"/>
                  <measurement group_id="O7" value="0.0" spread="0.0"/>
                  <measurement group_id="O8" value="0.0" spread="0.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Azithromycin Ophthalmic Solution, 1% -30 Minutes Post Dose</title>
        </group>
        <group group_id="E2">
          <title>Azithromycin Ophthalmic Solution, 1% -2 Hours Post Dose</title>
        </group>
        <group group_id="E3">
          <title>Azithromycin Ophthalmic Solution, 1% -12 Hours Post Dose</title>
        </group>
        <group group_id="E4">
          <title>Azithromycin Ophthalmic Solution, 1% -24 Hours Post Dose</title>
        </group>
        <group group_id="E5">
          <title>Moxifloxacin 0.5% Ophthalmic Solution-30 Minutes Post Dose</title>
        </group>
        <group group_id="E6">
          <title>Moxifloxacin 0.5% Ophthalmic Solution-2 Hours Post Dose</title>
        </group>
        <group group_id="E7">
          <title>Moxifloxacin 0.5% Ophthalmic Solution-12 Hours Post Dose</title>
        </group>
        <group group_id="E8">
          <title>Moxifloxacin 0.5% Ophthalmic Solution-24 Hours Post Dose</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eyelid Margin Crusting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedRA 10.1">Conjunctival Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Research</name_or_title>
      <organization>Inspire Pharmaceuticals, Inc.</organization>
      <phone>010-941-9777</phone>
      <email>kkuhn@inspirepharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
